Historical Valuation
Exact Sciences Corp (EXAS) is now in the Fair zone, suggesting that its current forward PS ratio of 5.41 is considered Fairly compared with the five-year average of -52.31. The fair price of Exact Sciences Corp (EXAS) is between 56.27 to 144.34 according to relative valuation methord.
Relative Value
Fair Zone
56.27-144.34
Current Price：102.11
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Exact Sciences Corp (EXAS) has a current Price-to-Book (P/B) ratio of 7.71. Compared to its 3-year average P/B ratio of 4.03 , the current P/B ratio is approximately 91.05% higher. Relative to its 5-year average P/B ratio of 4.19, the current P/B ratio is about 83.86% higher. Exact Sciences Corp (EXAS) has a Forward Free Cash Flow (FCF) yield of approximately 1.28%. Compared to its 3-year average FCF yield of 0.01%, the current FCF yield is approximately 11069.40% lower. Relative to its 5-year average FCF yield of -0.94% , the current FCF yield is about -236.13% lower.
P/B
Median3y
4.03
Median5y
4.19
FCF Yield
Median3y
0.01
Median5y
-0.94
Competitors Valuation Multiple
AI Analysis for EXAS
The average P/S ratio for EXAS competitors is 4.34, providing a benchmark for relative valuation. Exact Sciences Corp Corp (EXAS.O) exhibits a P/S ratio of 5.41, which is 24.51% above the industry average. Given its robust revenue growth of 20.05%, this premium appears sustainable.
Performance Decomposition
AI Analysis for EXAS
1Y
3Y
5Y
Market capitalization of EXAS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of EXAS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is EXAS currently overvalued or undervalued?
Exact Sciences Corp (EXAS) is now in the Fair zone, suggesting that its current forward PS ratio of 5.41 is considered Fairly compared with the five-year average of -52.31. The fair price of Exact Sciences Corp (EXAS) is between 56.27 to 144.34 according to relative valuation methord.
What is Exact Sciences Corp (EXAS) fair value?
EXAS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Exact Sciences Corp (EXAS) is between 56.27 to 144.34 according to relative valuation methord.
How does EXAS's valuation metrics compare to the industry average?
The average P/S ratio for EXAS's competitors is 4.34, providing a benchmark for relative valuation. Exact Sciences Corp Corp (EXAS) exhibits a P/S ratio of 5.41, which is 24.51% above the industry average. Given its robust revenue growth of 20.05%, this premium appears sustainable.
What is the current P/B ratio for Exact Sciences Corp (EXAS) as of Jan 10 2026?
As of Jan 10 2026, Exact Sciences Corp (EXAS) has a P/B ratio of 7.71. This indicates that the market values EXAS at 7.71 times its book value.
What is the current FCF Yield for Exact Sciences Corp (EXAS) as of Jan 10 2026?
As of Jan 10 2026, Exact Sciences Corp (EXAS) has a FCF Yield of 1.28%. This means that for every dollar of Exact Sciences Corp’s market capitalization, the company generates 1.28 cents in free cash flow.
What is the current Forward P/E ratio for Exact Sciences Corp (EXAS) as of Jan 10 2026?
As of Jan 10 2026, Exact Sciences Corp (EXAS) has a Forward P/E ratio of 120.66. This means the market is willing to pay $120.66 for every dollar of Exact Sciences Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Exact Sciences Corp (EXAS) as of Jan 10 2026?
As of Jan 10 2026, Exact Sciences Corp (EXAS) has a Forward P/S ratio of 5.41. This means the market is valuing EXAS at $5.41 for every dollar of expected revenue over the next 12 months.